Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition containing oleanolic acid acetate as an active ingredient for preventing or treating TLR- or IL-6-mediated diseases

A technology of IL-6 and active ingredients, applied to skin external preparations for good TLR and IL-6-mediated diseases, relates to the field of prevention or health-care functional foods containing the active ingredients, and can solve pathological and The genetic mechanism of action has not been clearly elucidated, etc., to achieve the effect without side effects

Active Publication Date: 2014-03-19
KOREA RES INST OF BIOSCI & BIOTECH
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Its pathology and genetic mechanism of action have not yet been clearly elucidated

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing oleanolic acid acetate as an active ingredient for preventing or treating TLR- or IL-6-mediated diseases
  • Pharmaceutical composition containing oleanolic acid acetate as an active ingredient for preventing or treating TLR- or IL-6-mediated diseases
  • Pharmaceutical composition containing oleanolic acid acetate as an active ingredient for preventing or treating TLR- or IL-6-mediated diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0092] Example 1: Preparation of Red Bean Extract and Fractions and Compounds of Chemical Formulas 1 and 2 separation and purification of

Embodiment 1-1

[0093] Example 1-1: Preparation of red bean extract

[0094] Wash red beans (red beans or adzuki beans) with water, dry them in a cool place, and grind them into powder using a Waring blender. Add 20 kg of powdered red beans to 100 L of methanol, cold soak and extract for 3 days, filter under reduced pressure with filter paper (Waterman Company, USA), and then use a vacuum rotary concentrator to filter the extract to The methanol solution was removed to obtain 450 g of extraction residue, which is the red bean extract.

Embodiment 1-2

[0095] Example 1-2: Preparation of Fractions

[0096] In order to separate the active fraction from the red bean extract prepared above, after the red bean extract was suspended in 1L of water, an equal amount of n-hexane was added, mixed and graded, and this process was repeated 4 times to obtain 1L of water-soluble Fraction and 4 L of n-hexane soluble fraction.

[0097] Next, the n-hexane-soluble fraction was concentrated under reduced pressure to obtain 50 g of n-hexane-soluble extract.

[0098] In addition, an equal amount of ethyl acetate was added to the 1L water-soluble fraction, mixed and classified, and this process was repeated 3 times, thereby re-obtaining 1L of water-soluble fraction and 3L of ethyl acetate-soluble fraction.

[0099] The obtained ethyl acetate soluble fraction was concentrated under reduced pressure to obtain 35 g of ethyl acetate soluble extract. The remaining water-soluble fraction was concentrated under reduced pressure to 35 g, which was us...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pore sizeaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating TLR- or IL-6-mediated diseases, containing oleanolic acid acetate or pharmaceutically acceptable salts thereof as an active ingredient, and to a pharmaceutical composition for preventing or treating TLR- or IL-6-mediated diseases and containing phaseoli semen extract, or a fraction thereof, which contains said compound or salts as an active ingredient. The phaseoli semen extract or compound according to the present invention is derived from a natural substance, which has long been used in natural medicine, and therefore causes no side effects. The phaseoli semen extract or compound inhibits the activity of TLR-3 and TLR-7 induced by Poly(I:C) and Poly(I), which are the synthetic analogues of dsRNA and ssRNA, blocks signaling pathways including NF-kappaB, and inhibits the transcriptional activity and phosphorylation of STAT3, which is an inflammation-related transcription factor activated by IL-6. Therefore, the phaseoli semen extract or compound of the present invention can be widely used in developing agents for preventing or treating TLR- and IL-6-mediated diseases, such as atopic dermatitis or arthritis.

Description

technical field [0001] The present invention relates to a pharmaceutical composition for preventing or treating TLR and IL-6-mediated diseases comprising oleanolic acid acetate as an active ingredient, more specifically, comprising oleanolic acid acetate or its Pharmaceutical composition for preventing or treating diseases mediated by TLR and IL-6, with medicinal salt as active ingredient; prevention or treatment containing red bean extract or fraction thereof containing said compound or its salt as active ingredient A pharmaceutical composition for a TLR and IL-6 mediated disease; and a method for treating a TLR and IL-6 mediated disease comprising the step of administering the composition to an individual suspected of having a TLR and IL-6 mediated disease. Furthermore, the present invention also relates to skin external preparations, health functional foods and personal hygiene products for preventing or improving TLR and IL-6-mediated diseases, which contain the active ing...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/56A61K36/48A61P29/00A61P11/06
CPCA61K36/48A61K31/19A61K31/56A61P1/02A61P11/00A61P11/06A61P13/12A61P17/00A61P17/06A61P19/00A61P19/02A61P19/06A61P19/10A61P25/00A61P27/02A61P29/00A61P3/00A61P31/04A61P31/10A61P31/14A61P31/16A61P35/00A61P35/02A61P37/02A61P37/04A61P37/06A61P37/08A61P43/00A61P9/00A61P9/10A47D13/025
Inventor 鲁文喆李雨松吴炫美金泳珉柳永培朴修珍李胜雄赵庚五
Owner KOREA RES INST OF BIOSCI & BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com